First Trust Mid Cap Growth AlphaDEX Fund (FNY)

FNY. Tracks the Nasdaq AlphaDEX Mid Cap Growth Index. Rules-based approach, fundamental-weighted portfolio. Not cap-weighted. Focuses on growth companies — faster expansion, improving sales, positive price momentum. Five metrics drive the ranking.

Three-month, six-month, 12-month momentum: price appreciation over those windows. One-year sales growth: how fast revenue is expanding. Sales-to-price ratio: valuation relative to top-line expansion. All five feed a single composite score. Bottom 25 percent of ranked stocks eliminated. Remaining growth candidates weighted by their scores.

Strong momentum plus rapid sales expansion plus reasonable valuation multiple gets higher weight. Slower growers, deteriorating trends, pure momentum chasers filtered out. Not just price action; fundamental sales strength required alongside appreciation. The methodology screens for real business momentum, not just speculation or technical moves.

Mid-cap growth occupies an inflection point. Larger and more stable than small caps. Smaller and faster-growing than the blue-chip names. FNY targets the operating, healthier segment. Real expansion, sustainable. The AlphaDEX process is mechanical about this distinction — a company needs both the sales metrics and the momentum to rank highly.

Holdings at least 90 percent in index components. Expense ratio 0.73 percent. Periodic rebalancing. Portfolio turns over more frequently than static holdings would — stocks move in and out of favor as rankings shift. Practical cost of maintaining a systematic, updated approach that captures changing leadership in the mid-cap growth universe.

AlphaDEX weighting versus cap-weighted growth differences matter. A smaller company with explosive sales growth and momentum gets higher weight than a larger, slower competitor. Over full market cycles, this has historically captured faster-compounding businesses before they graduate to large-cap status, where they fade as they mature. Rising-rate environments test this thesis sharply. When growth stocks underperform, FNY underperforms broad benchmarks. Known risk. The bet works best when growth trades in favor relative to value.

Sector exposure tilts toward technology, healthcare, industrials — the sectors where growth and momentum naturally reside. Any growth-focused portfolio will carry this tilt. FNY does not hide it; the tilt is built into the methodology.

Multi-cycle track record. Since mid-2000s. Performance depends on growth outpacing value. Whether mid-cap growth specifically delivers alpha. Historical data shows that AlphaDEX weighting has delivered some outperformance against cap-weighted growth indices in multiple cycles, though nothing is guaranteed and periods of growth underperformance reverse gains.

To evaluate the fund: current holdings and sector allocation on the fund fact sheet. Performance against Russell MidCap Growth and S&P MidCap 400 Growth indices. Whether AlphaDEX growth characteristics translate to realized outperformance over time. The prospectus covers the full index methodology, fee structure, and risk factors. Tracking error — the divergence between FNY’s returns and its benchmark — is another useful metric, as it shows how closely the fund matches its stated index.

Momentum and sales growth lead and lag with market cycles. FNY is a systematic, mechanical bet on growth fundamentals in the mid-cap band. Disciplined. Not a forecast. Not active management. Suits investors with moderate risk tolerance and a multi-year horizon who believe faster-growing companies deserve higher portfolio weight.